Table 2.
|
Group 2 (stage 1 and 2 COPD patients) |
Group 3 (stage 3 and 4 COPD patients) |
---|---|---|
(n = 20) | (n = 20) | |
Short acting β2 agonist |
6 |
12 |
Long acting β2 agonist |
12 |
18 |
Long acting anticholinergic |
7 |
15 |
Inhaler steroid |
6 |
18 |
N-acetyl systein |
2 |
7 |
Long term oxygen therapy |
2 |
10 |
Pulmoner rehabilitation | 0 | 7 |